Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.76 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
| ▸ | PDE1A | P54750 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143264 | 0.81 | MEN1 (0.67) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL8128164 | 0.81 | MEN1 (0.67) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL8128166 | 0.81 | MEN1 (0.67) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL8142359 | 0.81 | MEN1 (0.67) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL25249437 | 0.74 | PDE1A (0.69) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL8140480 | 0.73 | LMNA (0.58) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL897036 | 0.71 | PDE1A (1.00) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL1457311 | 0.70 | HTT (0.62) | MEN1LMNACYP1A1CYP1A2CYP3A4 | |
| SCHEMBL461786 | 0.70 | PDE2A (0.62) | MEN1LMNACYP1A2CYP3A4NFKB1 | |
| SCHEMBL9122584 | 0.69 | PDE1A (0.63) | MEN1LMNACYP1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| US-20230301968-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2023-09-28 | — | — | US | claimed |
| EP-3923936-B1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | ZEPHAPHARM LTD (GB) | 2023-08-09 | — | — | EP | claimed |
| EP-3972591-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| US-20220125765-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | ZEPHAPHARM LTD (GB) | 2022-04-28 | — | — | US | claimed |
| EP-3972591-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | Zephapharm Ltd. (GB) | 2022-03-30 | — | — | EP | claimed |
| WO-2003089656-A1 | METHODS AND COMPOUND MIXTURES FOR DETERMINING PROTEIN ACTIVITY USING NMR SPECTROSCOPY | AMERSHAM HEALTH AS (NO) | 2003-10-30 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1303615-A2 | FERMENTATION PROCESS FOR EPOTHILONES | Kosan Biosciences, Inc. (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020137152-A1 | Fermentation process for epothilones | KOSAN BIOSCIENCES, INC. | 2002-09-26 | — | — | US | claimed |
| EP-0659082-B1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER LAMBERT CO (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2002008440-A2 | FERMENTATION PROCESS FOR EPOTHILONES | KOSAN BIOSCIENCES, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| US-6294350-B1 | TREATING DISEASE CHARACTERIZED BY INCREASED LEVELS OF C-JUN HOMODIMERS, INCREASED HETERODIMERIZATION OF C-JUN WITH ANOTHER SIGNALING PEPTIDE, INCREASED LEVELS OF PHOSPHORYLATED C-JUN, AND/OR INCREASED PRESENCE OF JUN KINASE | DALHOUSIE UNIVERSITY (CA) | 2001-09-25 | — | — | US | claimed |
| WO-2001032156-A2 | METHODS FOR TREATING FIBROPROLIFERATIVE DISEASES | DALHOUSIE UNIVERSITY (CA) | 2001-05-10 | — | — | WO | claimed |
| EP-0659082-A1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | claimed |
| WO-1994005296-A2 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301968-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | CYP3A43, CYP1A2, CYP3A5 | MEN1 3838/4885LMNA 3527/4885CYP1A1 14/4885 |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | MEN1 4724/4885LMNA 2136/4885CYP1A1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.